Literature DB >> 21459903

Degree and frequency of inhibition in a routine real-time PCR detecting Pneumocystis jirovecii for the diagnosis of Pneumocystis pneumonia in Turkey.

Mert Döşkaya1, Ayşe Caner1, Aysu Değirmenci1, Nancy L Wengenack2, Ayşegül Yolasığmaz1, Nevin Turgay1, Seray Özensoy Töz1, Yüksel Gürüz1.   

Abstract

Routine laboratory diagnosis of Pneumocystis jirovecii is currently achieved by PCR in almost all laboratories with sufficient equipment due to its high sensitivity and specificity compared to staining methods. A current issue that limits the reliability and sensitivity of PCR is the degree of inhibition caused by inhibitory substances in respiratory samples. The present study aimed to analyse the degree and frequency of inhibition in real-time PCR detecting P. jirovecii in respiratory specimens submitted to a Pneumocystis pneumonia (PcP) diagnosis laboratory in Ege University Medical School, Turkey. Between July 2009 and December 2010, 76 respiratory specimens [63 bronchoalveolar lavage (BAL) fluid, 10 sputum samples, two tracheal aspiration fluid and one thoracentesis fluid] obtained from 69 PcP-suspected patients were investigated for the presence of P. jirovecii using real-time PCR targeting the cdc2 gene. Of these samples, 42 of the specimens were stained and examined by microscopy according to the request of the clinicians. PCR was positive in 15 specimens in the initial run. Of the remaining 61 samples, 41 of them were negative with positive internal inhibition controls (i.e. true-negative group). The frequency of inhibition in the initial run was 26.31 % (20/76) as determined by spiked negative controls. All of the inhibited samples were resolved after 1 : 2, 1 : 5, 1 : 10 and 1 : 20 dilutions. P. jirovecii was detected by PCR in two inhibited specimens after retesting with diluted samples which were also positive by microscopy. The incidence of P. jirovecii in respiratory specimens was 22.36 % (17/76) as determined by real-time PCR and 7.14 % (3/42) by microscopy. Overall, the incidence of P. jirovecii in respiratory samples was 23.68 % (18/76) as detected by both methods. In conclusion, inclusion of spiked positive controls in each sample and retesting with diluted samples to resolve inhibition increased the reliability of the real-time PCR assay in terms of determining false-negative results and influencing the treatment of the patient. Furthermore, results of the present study determined for the first time the frequency and degree of inhibition in a real-time PCR detecting P. jirovecii in respiratory specimens during routine diagnosis of PcP.

Entities:  

Mesh:

Year:  2011        PMID: 21459903     DOI: 10.1099/jmm.0.030775-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  4 in total

1.  Detection of Pneumocystis jirovecii by Quantitative PCR To Differentiate Colonization and Pneumonia in Immunocompromised HIV-Positive and HIV-Negative Patients.

Authors:  T Fauchier; L Hasseine; M Gari-Toussaint; V Casanova; P M Marty; C Pomares
Journal:  J Clin Microbiol       Date:  2016-03-23       Impact factor: 5.948

2.  Role of Pneumocystis jirovecii in patients with different pulmonary underlying condition using a nested-PCR.

Authors:  L Martínez Lamas; M T Pérez Rodríguez; I Álvarez Ramos; M E Bouza Soage; M P Figueroa Lamas; M Álvarez Fernández
Journal:  Rev Esp Quimioter       Date:  2018-06-29       Impact factor: 1.553

3.  Modified genome comparison method: a new approach for identification of specific targets in molecular diagnostic tests using Mycobacterium tuberculosis complex as an example.

Authors:  Alireza Neshani; Reza Kamali Kakhki; Mojtaba Sankian; Hosna Zare; Amin Hooshyar Chichaklu; Mahsa Sayyadi; Kiarash Ghazvini
Journal:  BMC Infect Dis       Date:  2018-10-12       Impact factor: 3.090

4.  Inhibition of polymerase chain reaction: Pathogen-specific controls are better than human gene amplification.

Authors:  Guillaume Roux; Christophe Ravel; Emmanuelle Varlet-Marie; Rachel Jendrowiak; Patrick Bastien; Yvon Sterkers
Journal:  PLoS One       Date:  2019-09-27       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.